2026-10-29 · contested story
HHS allows compounding of six experimental peptides over FDA scientists'
In October 2026, the Trump administration's Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides — including the popular injury-recovery duo BPC-157 and TB-500 — without fear of federal enforcement. This came despite objections from FDA career scientists who concluded there is scant evidence the substances are safe or effective, and after a reconstituted and divided FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted in July 2026 to recommend loosening restrictions on the peptides. The policy reverses a 2023 Biden-era decision that placed nearly 20 peptides in a restricted 'Category 2' designation. The action came from Kennedy's office rather than the FDA itself, and would allow compounding of peptides proposed to treat conditions including ulcerative colitis, insomnia, wound healing, inflammation, obesity, osteoporosis and migraines — none of which have undergone the large-scale clinical trials required for FDA drug approval.
How each side frames it
left
"Please don't inject yourself with bootleg peptides"
"It would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S."
"two women became critically ill after being injected with peptides the FDA had categorized as unsafe"
"more than a half-dozen people with connections to the peptide industry were added to the panel, including doctors, pharmacists or consultants who work in the field"
"The Great Peptide Cash Grab Has Begun"
center
"This comes despite objections from FDA career scientists who say there's scant evidence the substances are safe or effective."
"FDA staff have recommended against adding the seven substances, pointing to limited human evidence, uncertain formulations and unresolved concerns involving immune responses, contamination and product quality."
"The most important question to ask is not whether pharmacies should be able to compound these peptides, but whether the peptides have first been shown to be safe and effective for the uses being promoted"
"I would never recommend anybody to use something that hasn't been proven to be safe"
"Given the composition of the reconstituted committee, we believe the most probable outcome is that PCAC will recommend inclusion for some or all of the seven peptides, despite FDA staff's briefing documents."
right
"Millions could gain easier access to popular peptides after FDA panel vote"
"In my experience, patients report faster recovery and, interestingly, a range of additional benefits they weren't necessarily seeking"
"you do not solve a quality problem by forcing the market underground"
"unlike GLP-1 drugs — which were extensively studied and regulated — many peptides lack comparable evidence and oversight"
"it's time to put this decision back in the hands of the patient, the physician and the pharmacist"
What each side left out
The right left out — covered by the PBS NewsHour & Washington Post & The Week
- FDA career scientists' specific findings that there were no human studies for TB-500 and insufficient evidence for BPC-157
- conflict-of-interest concerns about the reconstituted advisory panel
The right left out — covered by the WIRED & Fortune & The Week & Stocktwits
- telehealth companies' financial stake and stock-price motivation (Hims & Hers acquired a manufacturing facility)
The left left out — covered by the Fox News & Bloomberg Law News & PR Newswire / Peppies & CBC
- the gray-market safety argument that regulated compounding is safer than imported Chinese 'research use only' vials
- poll finding that 52% of Americans support legal prescription peptide access vs only 3% opposed
The left left out — covered by the New York Post
- patient testimonials describing meaningful symptom relief (menopause, injury recovery)
The center left out — covered by the Salon
- RFK Jr.'s specific claim that the 2023 FDA action was 'illegal' because there was no safety signal
- former FDA officials' rebuttal that regulations require assessing both safety AND effectiveness
What's actually true?
[verified] An FDA advisory panel (PCAC) voted in July 2026 to recommend loosening restrictions on six of seven peptides reviewed, by votes around 8-6 with one abstention.
[verified] FDA career scientists recommended against adding all seven peptides to the compounding list, citing limited or absent human clinical evidence.
[verified] FDA reviewers found no human clinical studies for TB-500.
[verified] In 2023 under the Biden administration, the FDA placed nearly 20 peptides in Category 2 (restricted from compounding) citing safety risks including cancer and liver, kidney and heart problems.
[verified] The FDA added members with ties to the peptide industry to the advisory panel before the July meeting, raising conflict-of-interest concerns.
[verified] The October 2026 HHS policy came from Kennedy's office rather than the FDA, and uses enforcement discretion to allow temporary compounding of six peptides.
[verified] RFK Jr. described himself as a 'big fan' of peptides and said he used them with 'really good effect' on injuries, stated on the Joe Rogan podcast.
[verified] U.S. imports of peptide and hormone compounds from China reached roughly $328 million in the first three quarters of 2025, about double the prior year.
The narrative clash
Whether the 2023 FDA peptide restrictions were legally justified by a safety signal
Left: the agency's 2023 decision to ban certain peptides was supported by numerous documented safety concerns ... FDA regulations also require the agency to assess both safety and effectiveness before approving a substance for compounding
Right: It was illegal because they're not supposed to do that unless there's a safety signal ... And they didn't have a safety signal
Whether deregulation makes peptides safer or more dangerous
Left: allowing peptides on the market without clinical testing poses a 'profound threat' to FDA's decades-old system for vetting drugs
Right: allowing U.S. pharmacies to compound peptides would steer Americans away from unvetted products imported from China and other foreign countries
Whether the peptides themselves are dangerous or only the sourcing is
Left: These peptides have no data to support their safety and efficacy
Right: There is no clear evidence that specific peptides among the group [of 19] are inherently dangerous when used appropriately ... The greater concern lies not in the peptides themselves, but in how they are sourced, prescribed and used
80 sources analyzed
The Boston Globe The Washington Post STAT News New York Post Fox News Mother Jones NPR HCP Live New York Post City Journal Salon PBS NewsHour foreignpolicyjournal.com New York Post Fox News Common Dreams WIRED BBC News New York Post Fox News Salon NBC News 90.3 KAZU Richmond Times-Dispatch City Journal Vox The Week MedShadow Foundation City Journal The Boston Globe PBS NewsHour RealClearHealth City Journal Common Dreams CBC orrick.com Vox The Washington Post Stocktwits The Boston Globe PBS NewsHour Healthline Vox The Washington Post PR Newswire The New Republic The Washington Post KSBY News Mother Jones TradingView The New Republic Law360 The Boston Globe Fortune Common Dreams EIN Presswire The New Republic MedPage Today Mother Jones Endpoints News Vox Yahoo Mother Jones Bloomberg Law News Salon AAMC The Daily Beast Yahoo Finance Singapore Salon onbetterliving.com Common Dreams insights.citeline.com The Daily Beast nss G-Club The New Republic Pluang The Daily Beast ABS-CBN The Daily Beast Financial Times